Stockscreener 앱 받기
4.13
0.00%
0.00
시간 외 거래:
4.33
0.20
+4.84%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener
BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com
Healthcare companies chase cures and capital in South Florida - Sun Sentinel
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire
BioAge Labs Elects Directors at Annual Meeting - TipRanks
BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times
BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News
Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan
Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire
Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire
BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire
BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks
BioAge Labs, Inc Q1 Loss Narrows - Nasdaq
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus
Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
BioAge Labs, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- BIOA - ACCESS Newswire
1.05%
0.60%
자본화:
|
볼륨(24시간):